This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetics/Pharmacodynamics of Oral Salmon Calcitonin in Patients With Osteoarthritis

This study has been completed.
Information provided by:
Nordic Bioscience A/S Identifier:
First received: June 13, 2007
Last updated: NA
Last verified: June 2007
History: No changes posted
The purpose of this study is to expose patients with OA to calcitonin and to determine plasma calcitonin levels after administration of 0.6 mg and 0.8 mg oral calcitonin and 200 IU nasal calcitonin. Also the purpose is to assess the effect of different doses of oral calcitonin (0.6 mg and 0.8 mg oral) and 200 IU nasal calcitonin compared to placebo on serum CTX-I and CTX-II. Finally to assess the tolerance profile of different doses/formulations of oral calcitonin compared to placebo.

Condition Intervention Phase
Osteoarthritis Drug: Oral salmon calcitonin, salmon calcitonin nasal spray Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study.

Resource links provided by NLM:

Further study details as provided by Nordic Bioscience A/S:

Primary Outcome Measures:
  • Number of adverse events

Secondary Outcome Measures:
  • Changes in Urine CTX-I and CTX-II
  • Changes in serum osteocalcin

Study Start Date: October 2005

Ages Eligible for Study:   52 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Medical history and symptoms of knee osteoarthritis

Exclusion Criteria:

  • Any other disease or medication affecting the bone or cartilage.
  • Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering to the Protocol or completing the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00486317

Ballerup, Denmark, 2750
Sponsors and Collaborators
Nordic Bioscience A/S
Study Chair: Bente J Riis, M.D. Nordic Bioscience A/S
  More Information Identifier: NCT00486317     History of Changes
Other Study ID Numbers: SMC021A2110
Study First Received: June 13, 2007
Last Updated: June 13, 2007

Keywords provided by Nordic Bioscience A/S:
Osteoarthritis, oral salmon calcitonin, tolerability, biomarkers

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Salmon calcitonin
Calcitonin Gene-Related Peptide
Bone Density Conservation Agents
Physiological Effects of Drugs
Vasodilator Agents processed this record on September 21, 2017